



LUMOS
DIAGNOSTICS

ASX ANNOUNCEMENT

Lumos Appoints Thermo Fisher Scientific as US Distributor for FebriDx®

MELBOURNE, Australia (16 September 2024) – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care (POC) diagnostic technologies, has signed an agreement with Fisher Healthcare, a part of Thermo Fisher Scientific, to distribute FebriDx® in the United States (US).

FebriDx® is a rapid point-of-care (POC) respiratory test which delivers results in 10 minutes from a fingerstick blood sample. In July 2023, the US Food and Drug Administration cleared FebriDx® to be marketed in the US as an aid in the diagnosis of bacterial acute respiratory infection and differentiation from non-bacterial etiology. The test has been cleared for use by healthcare professionals with patients presenting in urgent care or emergency care settings and is intended to be used in conjunction with clinical signs and symptoms, including other clinical and laboratory findings, to evaluate patients for acute respiratory infection.

“We are very pleased to announce this partnership with Fisher Healthcare for FebriDx® distribution.,” said Doug Ward, CEO and Managing Director for Lumos Diagnostics. “We look forward to working together to accelerate the growth of FebriDx® via their network of customers across the US.”

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Lumos - Media Contact:

Haley Chartres – Australia
H^CK Director
haley@hck.digital
+61 423 139 163

Lumos - Investor Contact:

Jane Lowe
Managing Director, IR Department
ir@lumosdiagnostics.com
+61 411 117 774

Lumos - Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205, Australia
+61 3 9087 1598